Forsythiaside B Inhibits Myocardial Fibrosis Via Down Regulating TGF-β1/Smad Signaling Pathway

Jing Sun,Jiaxin Zhu,Lei Chen,Bingjing Duan,Ruyi Wang,Mengyuan Zhang,Jian Xu,Wenyuan Liu,Yunhui Xu,Feng,Wei Qu
DOI: https://doi.org/10.1016/j.ejphar.2021.174354
IF: 5.195
2021-01-01
European Journal of Pharmacology
Abstract:Forsythiaside B is the major ingredient of Callicarpa kwangtungensis Chun, and has been proven to protect myocardium from ischemia-reperfusion injury to achieve myocardial protection. However, the effect of forsythiaside B on adverse myocardial fibrosis remains unclear. In the present study, the myocardial fibrosis animal models were established induced by isoproterenol (ISO) to investigate whether forsythiaside B exhibited antifibrotic actions. Forsythiaside B was found to significantly improve the cardiac ejection fraction and fractional shortening rate of myocardial fibrosis mice compared with the normal saline group. In addition, forsythiaside B could lower the level of TGF-β1, the expression of α-SMA and collagen III. Forsythiaside B down-regulated the expression of Smad4 and the phosphorylation level of Smad3, which indicates that forsythiaside B could suppress myocardial fibrosis by inhibiting the TGF-β1/Smad signaling pathway. These results demonstrated that forsythiaside B could prevent myocardial fibrosis in ISO-induced mice, and may be a potentially rational therapeutic approach for the treatment of myocardial fibrosis.
What problem does this paper attempt to address?